Lepu Medical announced that Shanghai Minwei Biotechnology Co., Ltd., a holding subsidiary of the company, will license MWN105 injections with independent intellectual property rights to Sidera Bio Aps in Denmark for a fee. , the Danish company Sidera will receive exclusive rights to develop and commercialize on a global scale other than Greater China. In return, Shanghai Minwei Biotech will acquire 9.99% of the shares in the Danish company Sidera and will obtain licensing fees for MWN105 injections from Sidera in Denmark. The licensed product MWN105 injection is a GLP-1/GIP/FGF21 receptor triple agonist independently developed by Shanghai Minwei Biotech. It is currently undergoing clinical trials in China.

Zhitongcaijing · 10/31/2025 12:49
Lepu Medical announced that Shanghai Minwei Biotechnology Co., Ltd., a holding subsidiary of the company, will license MWN105 injections with independent intellectual property rights to Sidera Bio Aps in Denmark for a fee. , the Danish company Sidera will receive exclusive rights to develop and commercialize on a global scale other than Greater China. In return, Shanghai Minwei Biotech will acquire 9.99% of the shares in the Danish company Sidera and will obtain licensing fees for MWN105 injections from Sidera in Denmark. The licensed product MWN105 injection is a GLP-1/GIP/FGF21 receptor triple agonist independently developed by Shanghai Minwei Biotech. It is currently undergoing clinical trials in China.